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Due to the ongoing opioid epidemic, innovative scientific perspectives and
approaches are urgently needed to reduce the unprecedented personal and soci-
etal burdens of nonmedical and recreational opioid use. One promising opportunity
is to focus on the relationship between sleep deficiency and opioid use. In this
review, we examine empirical evidence: (1) at the interface of sleep deficiency
and opioid use, including hypothesized bidirectional associations between sleep
efficiency and opioid abstinence; (2) as to whether normalization of sleep defi-
ciency might directly or indirectly improve opioid abstinence (and vice versa); and
(3) regarding mechanisms that could link improvements in sleep to opioid absti-
nence. Based on available data, we identify candidate sleep-restorative therapeu-
tic approaches that should be examined in rigorous clinical trials. (Translational
Research 2021; 000:116)
Abbreviations: 5HT = serotonin; CB = cannabinoid; CBD = cannabidiol; CBTi = cognitive behav-
ioral treatment for insomnia; D2 = dopamine receptor 2 subtype; DSM-IV = Diagnostic and Sta-
tistical Manual version 4; eCB = endocannabinoid; EEG = electroencephalogram; FDA = Food
and Drug Administration; GABA = gamma-amino-butyric acid; HEAL = Helping to End Addic-
tion Long Term; IR = immediate release; HPA = hypothalamic-pituitary-adrenal; MBTi = mindful-
ness based treatment for insomnia; MOUD = medications for treating opioid use disorder;
NIH = National Institutes of Health; NMDA = N-methyl-D-aspartate; NREM = non-rapid eye
movement; OUD = opioid use disorder; OX = orexin; PSQI = Pittsburgh Sleep Quality Index; REM
= rapid eye movement; rTMS = repetitive transcranial magnetic stimulation; SNS = sympathetic
nervous system; SR = sustained release; SUDs = substance use disorders; tACS = transcranial
alternating current stimulation; tDCS = transcranial direct current stimulation; THC = delta-9-
tetrahydrocannabinol
RESPONDING TO THE OPIOID EPIDEMIC
Opioid overdoses, emergency department visits, and
deaths related to opioid use have risen precipitously
over the past 2 decades. These and other adverse conse-
quences of opioid use (eg, unemployment, social and
legal problems) are a major ongoing burden for indi-
viduals, families and society,1,2 leading to aggressive
federal, state and local policies and funding to combat
this crisis including the NIH Helping to End Addiction
Long-term (HEAL) Initiative (https://heal.nih.gov). It
has been estimated that opioid misuse cost the US
more than $2.5 trillion from 2015 through 2018.3
Substantial scientific evidence supports the effec-
tiveness of medications for treating opioid use disorder
(MOUD): methadone or buprenorphine are gold-
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standard agonist options for maintenance treatment and
naltrexone is an antagonist option for relapse preven-
tion. Despite the availability of these MOUD alterna-
tives, the rate of treatment engagement for OUD in the
US remains unacceptably low: only about 20% of
patients with OUD are receiving any form of treat-
ment,4-6 and few in the US receive MOUD.7-9 It is also
well established that longer retention in OUD treatment
is associated with improved outcomes including higher
rates of opioid abstinence, less mortality risk, and
lower healthcare utilization/costs.10-13 Nonetheless, an
unacceptably high proportion of patients with OUD in
treatment drop out; this can be driven by several factors
including patient’s non-preference for existing treat-
ments, side effects, or lack of efficacy.14 Patients who
receive prompt follow-up care after opioid detoxifica-
tion are at lower risk of subsequent mortality.15 Long-
acting naltrexone is effective for preventing relapse
after detoxification, but is presently used less often
than opioid agonist therapies.16
The US Food and Drug Administration (FDA)
recently emphasized the importance of expanding OUD
treatment alternatives, especially non-opioid options
that may have less misuse potential.17 Furthermore, the
FDA has advocated for a holistic scientific approach to
OUD, encouraging researchers to study and validate
alternative, clinically meaningful endpoints besides drug
abstinence. Among these phenotypes, remediation of
sleep deficiency has tremendous potential to improve
overall behavioral health and could partly mediate the
successful outcome of drug abstinence.
SLEEP DEFICIENCY AND OPIOID USE
Nomenclature. Throughout this review, we will use
the broad term “sleep deficiency” to encompass non-
restorative patterns of sleep including delayed sleep-
onset, sleep-maintenance problems (eg, difficulty
returning to sleep after awakening and/or early awak-
enings), disruption of regular cycling between non-
rapid eye movement (NREM) and rapid eye movement
(REM) phases, and diagnoses of insomnia and other
sleep disorders (eg, apnea, periodic leg movements).
Adopting this broader terminology can help to account
for large differences in methodology across studies.
However, when describing individual studies, we will
refer to the specific characteristics of the sleep defi-
ciency. Also, consistent with the literature and clinical
practice, we define the metric “sleep efficiency” as
(total sleep time  time in bed); we will refer to
improvements in sleep efficiency using this metric, and
normalization as reaching 85% or higher during an
8-hr sleep opportunity.18,19
Likewise, we will broadly refer to “opioid use” to
encompass the non-medical and recreational use of
opioids (ie, this review will generally not refer to
appropriate FDA-indicated use of prescription opioid
analgesics, because such behavior would not meet
diagnostic criteria for OUD19). Again, when describing
individual studies, we will use study-specific language.
Sleep deficiency and substance use disorders. Across
studies of individuals with varying substance use disor-
ders (SUDs), it has been reported or experimentally
demonstrated that sleep deficiency is related to increased
pain sensitivity,20-24 emotion dysregulation,25-27 and
impaired frontal-executive control and decision mak-
ing.28-33 Furthermore, sleep deficiency is associated
with increased propensity for lapse/relapse to substan-
ces34 including alcohol,35-38 tobacco/nicotine,26,39-41
cannabis,42-44 and methamphetamine,45 and has been
hypothesized to impair extinction of drug-environment
conditioning.46 However (as will be discussed in ’’Alle-
viating sleep deficiency as a pathway to improving opi-
oid abstinence’’), few clinical studies have explicitly
addressed the role of sleep deficiency in opioid craving
and relapse risk.
Fig 1 presents an overarching conceptual framework,
which is intentionally broader in scope than this focused
review, to situate our discussion in a more comprehensive
context. There are hypothesized bidirectional relation-
ships between sleep deficiency and opioid craving, opioid
use, and severity of OUD,47-51 and between sleep defi-
ciency and nociceptive behaviors52-56; although there are
obvious relationships between pain and opioid use, this is
not our emphasis here. These clinical problem areas 
sleep deficiency, pain, and opioid use are closely linked
via activation of stress-regulatory systems: sympathetic
nervous system (SNS), hypothalamic-pituitary-adrenal
(HPA) axis, and inflammatory processes.57 We also rep-
resent negative mood states in this model, which are asso-
ciated with these problem areas, but we touch only briefly
on these issues.
Sleep-related effects of opioid use and discontinuation.
Starting about 50 years ago, rodent studies of opioid
physical dependence and discontinuation were con-
ducted, in which morphine, methadone, or l-alpha-ace-
tyl-methadol were self-administered intravenously
while EEG sleep and wake periods were continuously
recorded across the 24-hr day; all 3 opioids disrupted
the timing and normal staging of sleep.58 Specifically,
sleep and wake episodes were systematically distrib-
uted within each inter-injection interval (3-hr with
morphine and 8 injections per day) irrespective of the
12/12 light-dark cycle. Within each interval, the initial
wake period was followed by solely NREM sleep, and
then REM sleep intermixed with NREM and wake, and
the next injection followed after a brief awakening.
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Early clinical studies produced results that paralleled
the animal studies above. In 3 separate double-blind
placebo-controlled studies, morphine,59 heroin,60 or
methadone61 were administered acutely to recently-
abstinent opioid-dependent research participants, who
would have otherwise entered a period of opioid with-
drawal. These opioid agonists dose-dependently
decreased total sleep time, stage 3-4 sleep time, and
REM sleep time. All 3 opioids also increased brief
arousals and frequency of sleep-stage changes (ie,
sleep fragmentation).
It is important to recognize that several factors may
affect the generalizability of these conclusions. First,
morphine, heroin and methadone are full mu-opioid ago-
nists, but they differ in their duration of action and ten-
dencies to produce receptor internalization; it is
unknown whether pharmacokinetics or receptor signal-
ing properties of different opioids may influence the
degree of tolerance to opioid-related sleep outcomes.
Second, we lack systematic data that would enable us to
conclude whether misuse of other common opioids (eg,
oxycodone, hydrocodone, tramadol, fentanyl) produce
the same effects on objectively-measured sleep effi-
ciency or subjective sleep quality. Third, population dif-
ferences (eg, OUD, low back pain, cancer) complicate
the interpretation of opioid agonist effects on sleep.
Opioid agonist-related sleep disruptions may also
occur by disturbing respiratory mechanisms. Opioids
cause hypoventilation, even controlling for cigarette
use that is highly prevalent among those with OUD.62
It should also be recognized that other drugs used via
smoking/inhalation routes (eg, marijuana, cocaine) and
through delivery vehicles (eg, vaping devices) that con-
tain respiratory-tract irritants could cause pulmonary
inflammation (with possible airway stenosis or cough-
ing) leading to sleep deficiency. Sleep itself normally
reduces respiratory drive and, combined with opioids,
the risk of sleep-disordered breathing (ie, central sleep
apnea) and the consequent disruption and fragmenta-
tion of sleep is heightened.63 In contrast to obstructive
sleep apnea, which predominates in obese men and is
related to excessive daytime sleepiness, central apnea
as a general rule (independent of opioid use) is most
typically is associated with insomnia.64 Central apnea
is characterized by cessation of both respiratory effort
and airflow and is related to awakening and not the
brief EEG arousal of obstructed breathing.
Discontinuation of chronic opioid use is associated
with protracted rebound of REM sleep, lasting 12 days
in rodents65 and with sleep deficiency and disturbed
sleep staging that can last many weeks in humans.66-68
Specifically, early-stage and protracted opioid with-
drawal are associated with increased sleep latency,
decreased total sleep time, decreased slow-wave sleep,
and early-phase opioid withdrawal is associated with
decreased REM sleep and increased REM latency.69
Fig 1. Conceptual model, illustrating hypothesized bidirectional relationships of sleep deficiency (focus of this
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Notably, these outcomes are qualitatively similar to
those produced by acutely administering mu-opioid
agonists to recently-abstinent, opioid-dependent indi-
viduals (see above). In other words, objective sleep
outcomes in states of opioid withdrawal and acute opi-
oid administration (to physically-dependent individu-
als) are comparable and one pharmacological state is
not inherently more deleterious than the other. As dis-
cussed in ’’Does treatment of opioid use disorder
improve sleep outcomes?’’, evidence is mixed as to
whether longer-term opioid agonist maintenance is
associated with the development of tolerance to these
objective measures of opioid-related sleep deficiency.
When people who were heroin-dependent and main-
tained on buprenorphine in an outpatient program were
discontinued from their treatment both sleep latency and
latency to REM sleep were prolonged and percent stage
3-4 sleep was reduced, compared to healthy controls.70 In
that study, after a week of buprenorphine 4 mg/day, sleep
patterns normalized. The improvement in sleep may be
dose-related as 4 mg improved sleep, but 8 mg/day did
not.71 In another study, methadone or buprenorphine
dose-tapering led to changes in actigraphic recordings (a
validated method of monitoring sleep and wake) indica-
tive of disrupted sleep and circadian rhythm.72 Finally, 2
case reports of patients with chronic pain using opioids
and with sleep-related disordered breathing suggest that
discontinuation of chronic opioid use may resolve the
breathing disturbance.73,74
Notably, the opioid antagonist naltrexone is not
expected to resolve opioid detoxification-associated
sleep disturbance. Naltrexone treatment has been asso-
ciated with sleep deficiency (all based on self-reported
symptoms) in newly-abstinent patients with opioid
dependence.75-78 Therefore, use of naltrexone follow-
ing opioid detoxification may not be addressing one
hypothesized cause of relapse (ie, continued sleep defi-
ciency). However, some comparative data suggest that
individuals maintained on naltrexone may experience
less insomnia than individuals maintained on metha-
done79 or buprenorphine/naloxone.80 The latter 2 stud-
ies used different sleep metrics, ie, polysomnogram79
vs. symptom reporting,80 which highlights the impor-
tance of using common objective sleep metrics in com-
paring OUD treatment effects on sleep.
Sleep deficiency and stress. Insomnia disorder, and
probably also comorbid insomnia that occurs in SUDs,
is hypothesized to reflect a 24-hr state of hyper-
arousal.81 Evidence suggests that this physiologic
hyperarousal is associated with activation of the sym-
pathetic nervous system (SNS) and hypothalamic-pitui-
tary-adrenal (HPA) axis. People with insomnia show
elevated levels of circulating catecholamines,82
increased metabolic rates,83 increased body tempera-
ture,84 enhanced cardiovascular risk,85 and smaller
resting pupil diameters.86 HPA axis activation in
insomnia is indicated by elevated levels of night-time
urinary free cortisol proportional to amount of wakeful-
ness during the night.82 An activated SNS and HPA
axis suggests a central mechanism, possibly involving
corticotropin releasing factor neurons.87,88 Thus, when
conducting studies that investigate links between sleep
and OUD, it is important to measure biomarkers of
HPA axis and SNS function including cortisol and cat-
echolamines. Among patients with chronic insomnia,
Vgontzas et al (1998) found that cortisol and catechol-
amine metabolites positively correlated with total
wake time and stage 1 sleep.82
Chronic sleep deficiency may modulate stress-reac-
tivity and its influence on craving and opioid use. In a
recent experimental study of persons with OUD, aver-
age self-reported nightly sleep duration moderated the
relationship between an acute laboratory stressor and
opioid cue-induced craving response.89 Likewise, in a
prospective observational study with daily measure-
ments, lower-than-usual self-reported sleep quality was
associated with greater opioid craving, a relationship
that was mediated by decreased positive affect.50
ALLEVIATING SLEEP DEFICIENCY AS A PATHWAY TO
IMPROVING OPIOID ABSTINENCE
Research findings reviewed above positively connect
sleep deficiency with opioid use. This evidence moti-
vates the strategy of using novel sleep-restoration strate-
gies to facilitate opioid abstinence (eg, in persons
receiving opioid agonist treatment) and/or prevent
relapse (eg, following detoxification or treatment with
naltrexone). Although the approach of treating sleep
deficiency to promote abstinence from substance use
has been explored in persons with other SUDs including
alcohol,90-92 cocaine,93-97 cannabis,98,99 and tobacco,100
this has not been systematically and thoroughly investi-
gated in persons with OUD. The overall model shown in
Fig 1 and the specific sleepopioid research literature
makes a compelling case for exploring, in patients with
OUD, non-opioid treatments that may reverse opioid
medication-induced sleep deficiency and thereby help
patients maintain opioid abstinence.
Does treatment that normalizes sleep improve opioid
use outcomes?. Behavioral approaches. Although there
is substantive evidence that behavioral treatments can
reduce sleep deficiency, data are lacking as to whether
improved sleep mediates or moderates substance
use.101 For instance, cognitive-behavioral treatment for
insomnia (CBTi) has been shown to improve sleep in
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persons without SUDs102,103 but, to our knowledge,
only one CBTi interventional study has been conducted
in people with OUD. In a small-scale randomized-
group study of methadone-maintained patients (11 per
group), the authors104 found that, over the 8-week trial,
CBTi significantly reduced sleep disturbance (mea-
sured with the Pittsburgh Sleep Quality Index
[PSQI]105 compared to a behavioral placebo group
(which focused on reducing conditioned arousal/frus-
tration associated with not initiating or maintaining
sleep). Similarly, mindfulness-based therapy for
insomnia (MBTi) has been shown to be effective for
improving sleep106 but there are no such studies with
OUD. In a small randomized trial, yoga added to
buprenorphine/naloxone treatment did not significantly
improve sleep over buprenorphine/naloxone alone, and
drug use outcomes were not reported.107 To our knowl-
edge, there are no published studies of other behavioral
treatments for sleep (eg, stimulus control, paradoxical
intention) that have been used in persons with OUD. In
short, we presently lack data from non-pharmacologi-
cal approaches to test the sleep-efficiency! opioid
abstinence hypothesis.
Neuromodulation. Previous studies have demon-
strated that patients with insomnia exhibit heightened
cortical excitability and hyperarousal, relative to
healthy controls.108-111 Thus, neuromodulation techni-
ques that inhibit cortical excitability/arousal could be
useful in treating sleep deficiencies. Guided by this
hypothesis, Babiloni et al (2020) systematically
reviewed studies that used repetitive transcranial mag-
netic stimulation (rTMS), transcranial direct current
stimulation (tDCS), or transcranial alternating current
stimulation (tACS) in sleep-deficient populations.112
These authors concluded that multiple (10-14) sessions
of inhibitory (1 Hz, 80-100% of resting motor thresh-
old) rTMS over the dorsolateral prefrontal cortex or
right posterior parietal cortex seem to improve subjec-
tive sleep quality and objective biomarkers (normaliza-
tion of sleep efficiency and NREM/REM cycling) in
patients with primary insomnia; however, studies
reviewed typically had a high risk of bias (eg, no sham
control), tDCS and tACS research is less technically
advanced than rTMS, and more rigorous clinical
research is needed. Similar conclusions were reached
in 2 other recent reviews of studies of rTMS for treat-
ing primary insomnia and other sleep disorders.113,114
Medication approaches. Sleep deprivation has wide-
ranging effects on the function of neurotransmitters and
their receptors,115,116 implying that neuropsychopharma-
cological interventions that reverse these changes could
be therapeutic. In the general population, current pre-
scribed medications for treating insomnia include ben-
zodiazepines, ‘z’-drugs (eg, eszopiclone, zaleplon,
zolpidem), gabapentin, antidepressants, melatonin
receptor agonists, and atypical antipsychotics.117-123
Yet, these hypnotic agents have limited efficacy, can
produce side effects (eg, cognitive impairment, dizzi-
ness), and some display misuse potential.
In persons with OUD, physicians have increasingly
eschewed prescribing benzodiazepines to treat sleep
deficiency due to the significant added risk of respiratory
depression, although some persons with OUD report
using benzodiazepines without a prescription for sleep
problems.124 Notably, the FDA (2016) issued a boxed
warning related to combining opioids and benzodiaze-
pines.125 These concerns of increased risk of respiratory
depression or misuse when prescribing medications for
insomnia to people with OUD lead to fewer insomnia
treatment options available to this population. Misuse of
gabapentin, a non-benzodiazepine with sedating and
analgesic properties, appears to be greater in combina-
tion with opioids than gabapentin alone.126
Findings are mixed concerning the efficacy of medi-
cations other than benzodiazepines for improving sleep
outcomes during opioid discontinuation. The a2-adren-
ergic agonist lofexidine has demonstrated some posi-
tive effects; however, these findings are not consistent.
For patients who had begun opioid detoxification,
lofexidine was found to reduce self-reported sleep
problems to a greater extent than methadone dose
tapering, measured over the course of 23-27 days of
inpatient opioid detoxification66; however, that study
allowed patients to choose which medication they
would receive and assessments were conducted at dif-
ferent times across groups (ie, 2 confounds), and other
studies have not found this benefit (see review, Gish
et al 2010).127 Quetiapine (an atypical antipsychotic
with actions at dopamine, serotonin, histamine, musca-
rinic, and adrenergic receptors) has also been examined
for this purpose. In a retrospective analysis of an obser-
vational study, 20% of outpatients undergoing opioid
discontinuation reported that quetiapine helped to
reduce their insomnia.128 Notably, in the same study,
patients also reported that quetiapine reduced their opi-
oid craving (74%), anxiety symptoms (48%), and
somatic pain (22%), so it possible that quetiapine
played an indirect role in reducing insomnia by attenu-
ating these other symptoms.
Slightly more research has examined the efficacy of
non-benzodiazepine medications for improving sleep
outcomes during opioid agonist treatment. Melatonin
may be effective in certain subsets of patients with
OUD. Patients maintained on methadone seeking to
stop their benzodiazepine misuse underwent 6 weeks
of gradual clonazepam dose-tapering alongside either
nightly melatonin treatment or placebo. The melatonin
group demonstrated significantly improved subjective
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sleep quality but only among patients who could not
discontinue their benzodiazepine use. For patients who
discontinued benzodiazepines (ie, only remained on
methadone), the melatonin had no effect on sleep qual-
ity (measured with the PSQI); however, this group had
a general improvement in sleep quality compared to
those who did not discontinue benzodiazepine use.129
Certain medications, included long-term benzodiaze-
pine use, have been associated with decreased levels of
endogenous melatonin.130 These findings suggest that
melatonin (which drives circadian rhythm) may
improve sleep quality in patients receiving opioid ago-
nist treatments, but only when they have concurrent
dysfunction in the circadian system. Support for this
hypothesis comes from a recent study, in which
patients with OUD in methadone treatment received
either 12 weeks of melatonin or placebo. Patients
receiving melatonin had significant self-reported sleep
improvements compared to placebo. Also, those
receiving melatonin had reductions in depression and
anxiety scores whereas the placebo group saw no
change.131 Notably, all participants entering the study
scored in the moderate-to-severe range on the Beck.
Depression Inventory. Depression can impair sleep out-
comes and is associated with lower levels of melatonin
and dysfunction of the melatonin system, further sup-
porting a role for melatonin within a subset of patients
with OUD.132
The atypical antipsychotic quetiapine has also been
found to decrease sleep problems among patients with
OUD maintained on methadone who also used meth-
amphetamine; however, the study also demonstrated
that patients in the quetiapine group (vs. placebo)
showed improvements in depression and some cogni-
tive functions. These findings, once again, suggest a
role for quetiapine in improving sleep outcomes in
patients with OUD, although these sleep-related effects
may be indirectly related to improvements in other
measures.133 Trazodone (a triazolopyridine derivative
with activity at serotonergic, histaminic, and adrener-
gic receptors), the second most commonly-prescribed
medication for treating insomnia in the United States,
has shown improvements in sleep latency, sleep effi-
ciency, and sleep duration in patients with insomnia.
Although commonly prescribed for insomnia in
patients with OUD, a double-blind, placebo-controlled
randomized trial with methadone-maintained patients
found that one month of trazodone treatment failed to
produce subjective or objective sleep-restorative
effects when compared to placebo.134 At present, there
are no studies that demonstrate trazadone’s efficacy in
this population. Zolpidem is the most commonly pre-
scribed sleep aid in the United States; however, it may
also be ineffective in this population. A small pilot
study examining the efficacy of zolpidem and mirtaza-
pine on sleep outcomes in methadone-maintained
patients found that zolpidem had the poorest sleep out-
comes even when compared to placebo. This same
study showed that mirtazapine (30 mg IR) improved
total sleep time, onset latency and sleep efficiency
(measured with actigraphy) relative to zolpidem
(12.5 mg SR), mirtazapine + zolpidem, and placebo.135
Notably, this study was insufficiently powered to fully
compare between these groups, so the results should be
considered preliminary. Nonetheless, the findings of
this study and previous studies indicate that people
with OUD should be considered a unique group when
evaluating appropriate medications to improve sleep-
related outcomes, and that the findings of studies in
clinical groups without OUD may not translate to this
population.
Does treatment of opioid use disorder improve sleep
outcomes?. Literature is mixed as to whether sleep
problems resolve with extended opioid agonist treat-
ment and, if so, through what mechanisms. Some early
studies found tolerance can develop to opioid agonist-
induced sleep disruption61,136: in those studies, sleep
fragmentation and REM sleep suppressive effects
diminished within weeks. However, more recent stud-
ies in methadone- or buprenorphine-treated patients
suggest that REM sleep remains suppressed70,137 and
there can be excessive daytime sleepiness.138,139
Importantly, ongoing sleep disturbance during OUD
treatment is often related to comorbid conditions,140,141
which are common in this population. For instance, one
uncontrolled study found that self-reported sleep prob-
lems improved over 90 days of buprenorphine treat-
ment; however, this could have been secondary to
observed reduction in depression symptoms.142 A
recent experimental study found that manipulating an
exogenous factor, opioid agonist treatment clinic atten-
dance schedule (earlier vs. later daytime hours), can
modulate sleep deficiency (measured with electronic
diary and actigraphy), with an earlier daily clinic atten-
dance requirement leading to greater sleep disrup-
tion.143 Importantly, that study also found ongoing
illicit opioid use was related to greater sleep disruption,
suggesting that opioid maintenance dosing require-
ments and ‘on-top’ illicit opioid exposures may inde-
pendently determine persistence of sleep deficiency
(see “Sleep-related effects of opioid use and discontin-
uation’’). Taken together, findings point to the clinical
importance of monitoring sleep problems using multi-
ple methods during opioid agonist treatment,144 while
accounting for substance use and co-occurring psychi-
atric (eg, depression) and medical (eg, respiratory) con-
ditions. Given the current state of research evidence, it
is not possible to make clear recommendations
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regarding the timing and/or efficacy of using medica-
tions for the treatment of OUD to resolve nonmedical
or recreational opioid use-related sleep disturbances.
MECHANISM-DRIVEN APPROACHES FOR FUTURE
INVESTIGATION
Table 1 summarizes promising therapeutic candi-
dates for future rigorous testing at the intersection of
sleep deficiency and OUD. When experimental data
are available, we highlight examples below of sleep-
restorative interventions (cognitive-behavioral, neuro-
modulation, medication) in people with OUD who are
receiving standard medication treatments (buprenor-
phine, methadone or naltrexone). In essence, this table
identifies potential treatment-combination studies that
could be designed for efficacy evaluations.
Evidence reviewed above (“Does treatment that
normalizes sleep improve opioid use outcomes?”)
suggests that medications with primary GABAergic
agonist actions are unlikely to be promising (ie, not
first-tier) candidates for managing sleep deficiency in
opioid agonist-maintained patients with OUD, due to
added risks of respiratory depression and misuse
potential, as well as cognitive impairment, accidents,
tolerance and rebound insomnia upon discontinua-
tion.145 However, results from one small-scale study
suggest a possible benefit of the benzodiazepine pra-
zepam in opioid-detoxified, naltrexone-maintained
patients.77 It is noteworthy that persons with OUD
who use sedatives only as prescribed appear to expe-
rience fewer opioid-related consequences,146 so there
is a subset of individuals with OUD for whom care-
fully-monitored, short-term hypnotic use could be
acceptable. Clinical use of sleep-promoting gabapenti-
noids, which act through voltage-gated calcium chan-
nels and NMDA receptors (unlike benzodiazepines),
requires careful assessment and risk stratification in
the context of chronic opioid use but is not univer-
sally contraindicated.147
Monoaminergic drugs. Medications with mixed
monoaminergic effects are extensively used to treat
neuropsychiatric conditions with affective features,
and may alter sleep deficiency (which is correlated
with those emotional disturbances). Extant data suggest
it may be worthwhile to conduct studies to further
investigate preliminary efficacy of the mixed-action
D2/5-HT2A antagonist, 5HT1A partial agonist, and
alpha1/histamine1 receptor antagonist quetiapine
128
and the mixed-action, 5HT2/3 antagonist and alpha2
antagonist, mirtazapine135 in patients with uncompli-
cated OUD. Quetiapine may also be effective in reduc-
ing sleep problems among OUD patients with co-
occurring psychostimulant use.133 Common receptor
mechanisms linking quetiapine and mirtazapine are the
5HT2 antagonist and 5HT1A agonist actions; the 5HT2/
3 receptor antagonism of mirtazapine may restore
5HT1A function that becomes desensitized during
chronic sleep deprivation.148
Melatonin receptor agonists. Melatonin is a hormone
synthesized by the pineal gland, and functions in the
suprachiasmatic nucleus to synchronize circadian
cycling of central and peripheral biological functions
including sleep/wake rhythm.149 Melatonin has prom-
ising effects on treating sleep deficiency and
Table 1. Treatment-combination matrix: testing candidate treatments for sleep deficiency in persons with opioid use disor-
der (OUD)
Primary medications for treating OUD


















Abbreviations: CBTi, cognitive behavioral treatment for insomnia; MBTi, mindfulness-based therapy for insomnia; rTMS, repetitive transcranial
magnetic stimulation; tDCS, transcranial direct current stimulation; tACS, transcranial alternating current stimulation.
Examples in the table refer to the few relevant published or ongoing clinical studies (see text for discussion).
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pain54,150,151 but, to our knowledge, only 2 clinical
studies of melatonin have been conducted in relation-
ship to sleep and opioid use. In one double-blind pla-
cebo-controlled, within-subject crossover trial,
melatonin (5 mg/day prior to bedtime) improved self-
reported sleep quality in methadone-maintained outpa-
tients with co-occurring benzodiazepine use; however,
melatonin had equivocal effects on benzodiazepine dis-
continuation.129 A double-blind, placebo-controlled,
parallel-group study found melatonin (10mg/day prior
to bedtime) supplementation during methadone main-
tenance improved subjective sleep, as well as depres-
sion and anxiety scores.131 The melatonin1/2 agonist
ramelteon would also be a reasonable candidate for
evaluation in this drug class, although there are no
studies to date.
Endocannabinoid modulators. Therapeutically-moti-
vated use of cannabinoid (CB) drugs has been increas-
ing in the general population, often in the absence of
clear scientific evidence. It is therefore timely to con-
sider whether drugs that modulate endocannabinoid
(eCB) function could be useful in treating sleep defi-
ciency. Δ9-tetrahydrocannabinol (THC), a CB1 recep-
tor-preferring agonist, when administered acutely can
decrease sleep onset latency, decrease waking after
sleep onset, increase slow-wave sleep and decrease
REM sleep time; however, repeated THC exposure can
lead to tolerance to these effects, and THC discontinua-
tion can produce rebound insomnia (review by Kesner
& Lovinger 2020).152 Thus, orthosteric CB1 receptor-
preferring agonists seem unlikely to be promising med-
ications for treating sleep deficiency.
Cannabidiol (CBD) acts via multiple eCB mecha-
nisms including CB1 negative allosteric
modulation,153,154 and inhibition of anandamide reup-
take,155 thereby increasing eCB signaling. CBD also
has non-eCB pharmacological actions including inhibi-
tion of adenosine reuptake156 and 5HT1A partial ago-
nism,157 each of which can promote sleep. At higher
doses, CBD is sedating.158,159 Thus, although CBD has
a complex pharmacology, its synergistic actions
(reviews by Campos et al 2012; Izzo et al 2009;
Mechoulam et al 2007) are likely to exert multiple
sleep-promoting actions.160-162
Literature reviews related to cannabinoid impact on
sleep efficiency as a primary outcome identified some
initial supportive (but often mixed) evidence; authors
have concluded that available studies were not of high
quality, but that data offer an adequate ‘signal’ for
designing well-controlled studies.163-165 There are vir-
tually no published clinical trials testing cannabinoid
impact on sleep efficiency in people with OUD. One
interview study found that patients with concurrent
DSM-IV cannabis and opioid dependence reported
more sleep disturbance than patients with only canna-
bis dependence166; thus, consistent with evidence noted
above regarding chronic THC exposure, excessive use
of cannabis may worsen sleep deficiency. A random-
ized, placebo-controlled trial found  in post hoc anal-
ysis  that, among opioid-detoxification patients who
received oral THC (dronabinol) in addition to
extended-release naltrexone, individuals who smoked
marijuana regularly (outpatient) reported less insomnia
and anxiety, and were more likely to complete the trial,
than those who did not smoke marijuana; dronabinol
itself did not improve sleep over placebo.167
Orexin receptor antagonists. Two research groups
simultaneously discovered a cluster of 50,000-80,000
neurons located in the lateral hypothalamus that project
widely throughout the brain to regulate sleep-wake,
feeding, stress-reactivity, and drug-motivated behav-
ior.168-170 These cells express 2 neuropeptides, named
hypocretin by the sleep research group and orexin
(OX) by the feeding research group. Lateral hypotha-
lamic OX neurons project to cholinergic and monoam-
inergic systems, stimulating arousal and motivation.
Orexin comes in 2 isoforms, orexin-A and orexin-B,
with 50% sequence homology, derived from the
same precursor protein, prepro-orexin; these isoforms
bind to 2 subtypes of G protein-coupled receptors,
orexin-1 (OX1) and orexin-2 (OX2). Orexin A has
slightly higher affinity for OX1 than OX2 receptors,
whereas orexin B has much higher affinity for OX2
than OX1 receptors.
The functional/behavioral significance and specific-
ity of OX receptors is not clearly defined.170 Pre-clini-
cal models suggest that OX2 receptors are primarily
involved in maintaining wakefulness and
arousal.171-175 Clinically, OX receptor antagonists are
being developed; the dual OX1/2 antagonist, suvorex-
ant, is the first-in-class FDA-approved hypnotic.176-178
Experiments have not directly parsed whether
suvorexant’s OX2 or OX1 antagonism mediates its hyp-
notic effects; however, the OX2 selective antagonist
seltorexant (an investigational drug) improves sleep in
people with insomnia, which suggests OX2 antagonism
is necessary for suvorexant’s hypnotic effects, as does
pre-clinical literature.170,179-181
Suvorexant is effective for treating primary sleep-
onset and/or sleep-maintenance insomnia in healthy
persons.182,183 Notably, suvorexant improves sleep
maintenance via sustained reduction of wake across the
8-hr sleep period, measured electrophysiologically as
sleep efficiency (sleep time  time-in-bed) or waking
after sleep onset. That effect, in turn, likely will stabi-
lize the ultradian rhythm of NREM-REM sleep, which
is disrupted in SUDs (ie, stage 3-4 and REM distur-
bance). Efficacy of suvorexant for promoting drug
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abstinence or preventing drug relapse directly, or indi-
rectly by improving sleep efficiency, has not yet been
evaluated among individuals with SUDs. As noted
above, evidence indicates OX2 (more so than OX1)
receptor antagonism mediates improvements in sleep
maintenance. In contrast, OX1 (more so than OX2)
antagonism attenuates stress-, cue-, and priming-
induced reinstatement of drug seeking.184,185 Few ani-
mal studies have tested whether OX2 antagonists block
drug reinstatement/ seeking, but some studies demon-
strate a positive effect.186-188 Thus, it is possible that
both OX1 and OX2 receptors modulate drug relapse-
like behaviors, independent of sleep-wake function.
Accordingly, dual OX antagonism could be a unique
strategy to target both insomnia and drug relapse. To
date, clinical studies on the efficacy of suvorexant have
focused solely on treating insomnia disorder; none
have addressed the utility of suvorexant to improve
sleep as an indirect means of reducing the risk of sub-
stance relapse, although this approach has recently
been suggested for alcohol use disorder,189 comorbid
cocaine and alcohol use disorders,190 and OUD.191,192
Our research team is presently conducting a random-
ized, placebo-controlled, mechanistic clinical trial to
assess whether suvorexant (10 mg and 20 mg at bed-
time) dose-dependently modulates sleep efficiency
(following opioid detoxification, allowing for
extended-release naltrexone maintenance) and subse-
quent opioid abstinence (across 3 months of weekly
outpatient follow-up visits) in people with OUD
(NCT04262193). We hypothesize that treatment aimed
at improving sleep efficiency (ie, reducing disruptive
effects of wake intrusions on normal sleep staging) is a
key mechanism for reducing the risk of drug relapse.
Two other ongoing placebo-controlled randomized tri-
als are examining whether suvorexant can increase
total sleep time among patients with OUD undergoing
supervised withdrawal (NCT03789214), and prevent
relapse in recently-abstinent patients who are main-
tained on extended-release naltrexone or methadone
(NCT04287062).
In the alcohol use disorder literature, 2 predictors of
relapse are deficient NREM sleep (ie, reduced age-cor-
rected NREM stage 3-4 sleep) and shortened REM
onset69,193; again, this has not studied with opioids.
Both these effects directly relate to sleep maintenance
and the normal NREM-REM ultradian rhythm. Nor-
malization of ultradian rhythm by suvorexant (relative
to placebo) should be reflected in REM latency of 80-
120 min and REM percent of 18-24%.18 Notably,
chronic opioid use and discontinuation both disturb
sleep and its rhythms in 2 ways: (1) disruption of circa-
dian timing of sleep such that sleep is tied to the user’s
opioid intake irrespective of light-dark cycle; and (2)
disruption of ultradian rhythm within sleep, the normal
NREM-REM cycling. Thus, in our ongoing project
(NCT04262193), we are anchoring sleep to the dark
cycle with suvorexant and a fixed light-dark cycle with
no daytime sleep, to increase likelihood of normal
ultradian rhythmicity by suppressing wake intrusion
throughout the 8-hr sleep period. We predict one or
both suvorexant doses will produce more rapid resolu-
tion of this ultradian disturbance than placebo, ie, sleep
will normalize across assessment nights on the inpa-
tient unit. We will test whether normalization of sleep
efficiency predicts weekly opioid abstinence over a 3-
month outpatient period.
CONCLUSIONS
Consistent with our conceptual model (Fig 1), the evi-
dence reviewed here indicates that sleep deficiency and
opioid use are likely bidirectionally linked, with addi-
tional bidirectional contributions (outside the scope of
this review) of pain and affective distress. Although
research findings suggest that sustained opioid absti-
nence can ultimately improve sleep efficiency, opioid
agonist or naltrexone treatment for OUD may itself pre-
vent full resolution of sleep deficiency. Thus, it is essen-
tial to develop and test non-opioid (including behavioral
and neuromodulation) approaches in this clinical popu-
lation. Presently, there are a few promising medication
options including suvorexant, mirtazapine and quetia-
pine, and other possible targets (eg, melatonin receptor
agonists, eCB modulators) although all require rigorous
testing. Furthermore, systematic investigations are
needed to establish whether normalization of sleep effi-
ciency is necessary for, or simply contributes to, opioid
abstinence and recovery of global function. Such studies
will need to account for the influence of demographic
factors (eg, sex, race, age), psychiatric conditions (eg,
depression, anxiety) and medical conditions (particu-
larly, but not limited to, pulmonary disorders). In this
way, we will be able to translate findings from mecha-
nism to clinical application.
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